Inpatient Rehab: How Long, How Much, and What Actually Works

Search for "inpatient rehab" and you will find two entirely unrelated kinds of care. One is post-acute medical rehabilitation — inpatient rehabilitation facilities where people recover after a stroke, a joint replacement, or a serious injury, doing physical, occupational and speech therapy. The other, and the subject of this page, is residential treatment for substance use disorder. The phrase is identical; the medicine has almost nothing in common. If you arrived here looking for rehabilitation after surgery or stroke, that care is arranged through the discharging hospital.

Residential addiction treatment means living at a facility for a defined period — typically thirty to ninety days — inside a structured clinical programme. In the ASAM framework it spans Level 3.1 (clinically managed low-intensity residential), Level 3.5 (clinically managed high-intensity), and Level 3.7 (medically monitored intensive inpatient, with 24-hour nursing). The defining feature is not the therapy on offer, which largely also exists in outpatient care. It is the removal of the environment: the people, places, supply and routine that sustained the pattern are simply unavailable for the duration.

The two are often presented as a preference. They are not. They are different intensities on a continuum, and the honest comparison is about what each can and cannot contain.

This is not decided by how much someone drinks or uses. ASAM assesses six dimensions, and a serious problem in any one of them can indicate residential care even when the others look manageable.

Alcohol accounts for a large share of residential admissions, and for a specific clinical reason rather than a cultural one. Alcohol withdrawal is one of the few withdrawals that can kill. Symptoms typically begin six to twenty-four hours after the last drink; seizure risk concentrates in the first forty-eight hours; delirium tremens, when it occurs, usually appears between forty-eight and ninety-six hours and is a medical emergency. Outpatient care cannot observe someone through that window.

Inpatient alcohol treatment therefore usually begins with medically supervised withdrawal management and then continues into the residential programme proper. That continuity matters: a person who detoxes in one place and is discharged to arrange treatment elsewhere frequently never arrives.

Three medications are FDA-approved for alcohol use disorder, and they are markedly underused. Naltrexone reduces heavy drinking and craving, available as a daily tablet or monthly injection. Acamprosate supports abstinence once withdrawal has resolved and is often chosen where liver function is a concern. Disulfiram produces an aversive reaction to alcohol and suits a specific, motivated subset, particularly with supervised dosing. A residential programme that discharges someone with alcohol use disorder without having discussed all three has left the most evidence-backed tool in the box.

Programme lengths are largely inherited from insurance history rather than from biology — the twenty-eight day model has more to do with mid-century coverage design than with any clinical threshold. What the research does support is that duration predicts outcome. NIDA states plainly that participation for less than ninety days is of limited effectiveness, and that longer episodes are recommended for maintaining positive outcomes.

Programmes differ, but the shape is remarkably consistent, and knowing it removes a good deal of the fear that keeps people from going.

Mornings start early and deliberately so — restoring sleep and circadian rhythm is treatment, not scheduling. A typical morning runs a check-in or reflection group, breakfast, then the day's first clinical block: usually group therapy, which does more of the work than most people expect. Individual therapy generally happens two or three times a week rather than daily, which surprises people who imagined the reverse. Afternoons carry psychoeducation, specialised groups such as trauma or relapse prevention, and physical activity. Evenings are lighter — peer support meetings, reflection, structured free time.

Family involvement is usually scheduled rather than casual: a family programme, therapy sessions, or defined visiting periods. Medical and psychiatric review continues throughout, with medication adjusted as the picture clarifies once substances are out of the system. The consistent surprise for new arrivals is how little unstructured time exists — and how much of the therapeutic effect comes from that structure rather than from any single session.

Early departure is the most under-discussed risk in residential treatment. The first days combine physical discomfort, a sudden loss of autonomy, the shock of communal living, and the arrival of emotions that substances were managing. Around the same moment, acute withdrawal resolves and the person feels physically better. Feeling better while feeling trapped is precisely the combination that produces a decision to leave.

This is worth naming in advance for two reasons. First, knowing the pattern is protective — expecting day three or four to be the low point makes it survivable rather than evidence that the place is wrong. Second, it is a fair question to ask a programme: what is their early-departure rate, and what do they do when someone wants to go? A programme that has thought about this has answers. One that treats it as a character failure has not.

For anyone with genuine professional obligations, this is the decisive practical question, and it is remarkably hard to get answered from a website. Whether a programme allows phones at all — and from which day — varies enormously: policies run from complete confiscation for the entire stay, through phased access earned over time, to scheduled daily windows with a laptop in a private room. All three exist. None of them is disclosed on most programme pages, which is why the question has to be asked explicitly.

There is a real clinical argument behind restriction: the phone is where the supply, the using contacts, and much of the stress live, and early separation from it genuinely helps. There is an equally real counter-argument: someone who refuses treatment entirely because they cannot vanish for a month receives no treatment at all, and a policy that produces that outcome has not protected anyone.

Ask these five things directly, and ask them before any deposit. What is the phone policy in the first week, and how does it change after that? Is laptop use permitted, and where? Can I take scheduled calls, and with how much notice? Is there private space to work, or only communal areas? And what happens if a genuine emergency arises at my company — who decides? Programmes accustomed to treating executives and clinicians answer these fluently. Hesitation is itself informative.

It would be dishonest for this site to pretend comfort is irrelevant. Private rooms mean sleep, and sleep is genuinely therapeutic in early recovery. Lower staff-to-patient ratios mean more individual therapy and faster psychiatric review. Good food matters more than it sounds when someone is nutritionally depleted. Discretion protects careers and families, and for people whose alternative is refusing care altogether because they cannot risk recognition, that protection is clinical rather than cosmetic.

The line worth holding is this: comfort improves retention, and retention improves outcomes — but comfort is not itself treatment. A beautiful residence with thin clinical staffing, no psychiatric coverage, and no medication prescribing is a worse choice than a plain one with all three. The questions that separate them are unglamorous: who is on site overnight, who prescribes, how often does a psychiatrist actually see patients, and what is the accreditation. Ask those first, and let the photographs be the tiebreaker rather than the argument.

This deserves a direct answer rather than a reassuring one. Addiction is a chronic, relapsing condition, and NIDA places relapse rates for substance use disorder at 40 to 60 per cent — squarely in the range reported for asthma and hypertension, conditions nobody describes as untreatable. A relapse indicates that treatment should be resumed or adjusted, in exactly the way a returning asthma symptom does.

What genuinely moves the odds is reasonably well established. Duration of engagement matters more than intensity — the ninety-day threshold recurs throughout the literature. Medication, where indicated, changes outcomes substantially for opioid and alcohol use disorder, and remains underused in residential settings. Continuing care after discharge is close to decisive, and a programme without a concrete step-down plan is handing back the hardest part unsupported. And treating co-occurring psychiatric illness concurrently rather than sequentially is what separates a durable result from a revolving door.

What no honest programme promises is a cure, a guaranteed success rate, or a number derived from its own unaudited follow-up. Published success percentages in this industry are marketing rather than measurement, and a programme quoting one should be asked how it was calculated, who was counted, and what happened to the people who could not be reached.

Residential treatment is priced per day, and the range across the market is enormous — from state-funded programmes at no cost to private residences billing several thousand dollars a day. A daily rate on its own is close to meaningless: the comparison only becomes real once you know the ASAM level, the staffing, whether medical and psychiatric care are included or billed separately, and what the figure covers on the day of admission and discharge.

On insurance, federal parity law prohibits applying substance use disorder benefits more restrictively than medical and surgical benefits. In practice, residential is the level insurers examine most closely, and authorisation is granted in reviewed increments rather than for a whole stay up front. That has a practical consequence worth understanding: continued authorisation depends on documentation from the treating programme — ASAM-based justification across all six dimensions and evidence of ongoing medical necessity. A programme experienced in concurrent review is worth considerably more than it appears on a brochure.

Most serious private residences are out of network. Where that is the case, the questions that decide the real number are the out-of-network residential benefit, the deductible position, the out-of-pocket maximum, and whether a single-case agreement is achievable. Our carrier guidance works through exactly these questions for Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare and Humana.

Six questions that separate programmes quickly, none of which require clinical training.

The measure of a residential stay is not how it felt on discharge day. It is whether the person is still in treatment three months later. Everything about the discharge plan should be built with that in mind, and it should be settled weeks before the end rather than in a final meeting.

A realistic plan usually combines several things: a step down to partial hospitalisation or intensive outpatient rather than straight to nothing; medication for opioid or alcohol use disorder, decided explicitly rather than omitted by default; continued psychiatric care where a co-occurring condition exists; and a living situation that is not the environment that produced the problem — which for some people means sober living for a period, and for others means changes at home negotiated during family work.

The pattern to avoid is the one that recurs most: an excellent, expensive residential stay, a discharge with a list of phone numbers, and a relapse inside a month. That outcome is rarely a failure of the residential programme itself. It is the predictable result of treating a chronic condition with an intensive episode and no continuing care.